CytoDyn CEO says FDA has offered 'a good path forward' for its HIV drug

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassen tells Proactive Investors the biotech held a productive phone conversation with the FDA in which it won key concessions for its flagship HIV drug leronlimab.

Pourhassen says regulators offered 'a good path forward' for leronlimab, as they recognized the higher dosage of 700mg in a monotherapy trial for leronlimab, an injectable antibody that takes aim at HIV, had a much higher response rate than the 350mg dose used in a combination therapy trial. Pourhassen says the company will now submit a Biologics License Application (BLA) to move the drug forward.

Quick facts: CytoDyn

Price: $0.43

Market: OTCQB
Market Cap: $157.53 m

More on this story


e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 2 hours ago

2 min read